Núcleo de Pesquisa de Produtos Naturais, Universidade Federal do Rio de Janeiro, 21941-902, Rio de Janeiro, RJ, Brazil.
Expert Opin Ther Pat. 2012 Oct;22(10):1111-21. doi: 10.1517/13543776.2012.724062. Epub 2012 Sep 13.
Influenza viruses are common agents of flu outbreaks, epidemics, and pandemics that have occurred through the centuries. Prevention and control of flu are of great clinical importance, since they cause serious damage to health, with a consequent impact on quality of life and economy of a country. Resistance against the current drugs justifies the development of new anti-influenza molecules. Flavonoids exhibit significant activity against flu through their anti-inflammatory and antiviral properties. The profile of these molecules makes them particularly promising as therapeutic agents against flu.
This review focus on the activity of flavonoids on different influenza virus targets as well as their use in patented pharmaceutical formulations. Twenty-one patents of these compounds for prophylaxis and treatment of influenza infection are discussed.
The H1N1 influenza pandemic in 2009 resulted in a significant increase in the number of patents claiming pharmaceutical formulations for prophylaxis and treatment of flu. The research advances on flavonoids showing anti-influenza activity and the efforts made by researchers and industries consolidate the interest on new alternatives for the therapy of an infectious disease that represents a serious public health problem throughout the world.
流感病毒是导致流感爆发、流行和大流行的常见病原体，这些情况在过去的几个世纪中时有发生。预防和控制流感具有重要的临床意义，因为它们会对健康造成严重损害，从而对一个国家的生活质量和经济产生影响。由于当前药物的耐药性，有必要开发新的抗流感分子。黄酮类化合物通过其抗炎和抗病毒特性对流感表现出显著的活性。这些分子的特性使它们作为治疗流感的药物具有很大的潜力。
本篇综述重点介绍了黄酮类化合物对不同流感病毒靶标的作用及其在专利药物制剂中的应用。讨论了这两种化合物用于预防和治疗流感感染的 21 项专利。
2009 年 H1N1 流感大流行导致声称具有流感预防和治疗作用的药物制剂的专利数量显著增加。具有抗流感活性的黄酮类化合物的研究进展以及研究人员和行业的努力，巩固了人们对治疗这种传染病的新替代方法的兴趣，因为它是全世界严重的公共卫生问题。
